Cabot Microelectronics Corporation to Participate in Topeka Capital Markets Industrials & Materials Conference
September 08, 2014 11:00 ET
|
CMC Materials
Aurora, IL, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Cabot Microelectronics Corporation (NASDAQ:
CCMP), the world's leading supplier of chemical mechanical
planarization (CMP) polishing slurries and a...
Arch Therapeutics Announces Positive Preclinical Data From an Independent Study of AC5 Surgical Hemostatic Device(TM) in Animals on Blood Thinners
September 08, 2014 07:57 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Sep 8, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, announced that an independent...
Arch Therapeutics Will Present at the 2014 Aegis Capital Healthcare Conference in Las Vegas, NV September 10-13th, 2014
September 02, 2014 07:58 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Sep 2, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company") today announced it will be featured as a presenting company at the 2014 Aegis Capital...
Arch Therapeutics Will Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014
August 26, 2014 07:58 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Aug 26, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), today announced it will be featured as a presenting company at the 16th Annual Rodman...
Arch Therapeutics Announces Positive Preclinical Data From Its Study of AC5 Surgical Hemostatic Device(TM) in Animals on Blood Thinner
August 25, 2014 07:58 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Aug 25, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ for potential use in bleeding...
Arch Therapeutics Announces Third Quarter 2014 Results
August 06, 2014 07:29 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Aug 6, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic...
Arch Therapeutics Announces Collaboration With University College Cork School of Pharmacy
July 22, 2014 08:30 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Jul 22, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, has entered into a new...
Arch Therapeutics Selects BSI as Its European Union Notified Body
July 15, 2014 08:30 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Jul 15, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a...
Arch Therapeutics Appoints Richard Davis as Chief Financial Officer
July 07, 2014 18:06 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Jul 7, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a...
Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at European Summit for Clinical Nanomedicine and Targeted Medicine in Basel, Switzerland on June 23
June 16, 2014 08:15 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Jun 16, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a...